CJC-1295 + Ipamorelin
Research Use Only
All products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.
CJC-1295 + Ipamorelin Overview
CJC-1295 + Ipamorelin is a research blend of two growth-hormone-secretagogue peptides. CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analog, and Ipamorelin is a selective growth-hormone secretagogue. The combination is studied for complementary signaling within the GH axis in preclinical models.
History
CJC-1295 was developed as a long-acting GHRH analog, while Ipamorelin was characterized as a selective, well-tolerated secretagogue. Research has paired the two to study additive effects on pulsatile signaling in controlled experimental systems.
Research Findings
The blend has been studied for its influence on the growth-hormone axis, with reported roles in receptor signaling, secretory pulse dynamics, and downstream metabolic pathways in preclinical research models.
Key Areas of Research:
- Endocrine: GH axis, receptor signaling
- Secretory: pulse dynamics, secretagogue activity
- Metabolic: downstream pathway dynamics
- Systemic: viability, pathway resilience
References
- Synthesis & Characterization. Solid-phase peptide synthesis, purification, and analytical confirmation of identity and purity.
- Preclinical Research. Reported activity across structural, vascular, and systemic models in controlled experimental settings.
- Stability Studies. Lyophilized stability and reconstitution behavior under controlled cold-chain storage.
- Analytical Verification. Third-party HPLC and mass-spectrometry verification of mass, identity, and purity.
